Nivolumab-associated Lambert-Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor

MeSH terms

• Amifampridine / therapeutic use
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Calcium Channels, P-Type
• Calcium Channels, Q-Type
• Cerebellar Diseases / chemically induced*
• Cerebellar Diseases / drug therapy
• Cerebellar Diseases / immunology
• Cerebellar Diseases / physiopathology
• Cerebellar Neoplasms / secondary
• Cerebellar Neoplasms / therapy*
• Female
• Glucocorticoids / therapeutic use
• Humans
• Immune Checkpoint Inhibitors / adverse effects*
• Immunoglobulins, Intravenous / therapeutic use
• Immunologic Factors / therapeutic use
• Lambert-Eaton Myasthenic Syndrome / chemically induced*
• Lambert-Eaton Myasthenic Syndrome / drug therapy
• Lambert-Eaton Myasthenic Syndrome / immunology
• Lambert-Eaton Myasthenic Syndrome / physiopathology
• Lung Neoplasms / diagnostic imaging
• Lung Neoplasms / pathology
• Lung Neoplasms / therapy
• Lymph Nodes / diagnostic imaging
• Magnetic Resonance Imaging
• Middle Aged
• Nerve Degeneration / chemically induced*
• Nerve Degeneration / drug therapy
• Nerve Degeneration / immunology
• Nerve Degeneration / physiopathology
• Neuroendocrine Tumors / secondary
• Neuroendocrine Tumors / therapy*
• Neuromuscular Agents / therapeutic use
• Nivolumab / adverse effects*
• Positron Emission Tomography Computed Tomography
• Prednisone / therapeutic use
• Radiosurgery
• Radiotherapy
• Rituximab / therapeutic use
• Small Cell Lung Carcinoma / diagnostic imaging
• Small Cell Lung Carcinoma / secondary
• Small Cell Lung Carcinoma / therapy
• Tomography, X-Ray Computed